Viking’s Obesity Data Makes Dosing Frequency the Next GLP-1 Battleground
VK2735 preserved most induction weight loss with every-other-week and monthly dosing in an early study. Roche's enicepatide delivered 15.5% weight loss alongside a 2.65-point HbA1c reduction in type 2 diabetes. The two programs are competing on different economic burdens.
Viking Therapeutics and Roche released metabolic-drug data on September 22 that broaden the competitive field beyond a single ranking of maximum weight loss.
Viking's VK2735 produced roughly 16%-19% mean weight loss after 21 weeks of weekly induction dosing in its maintenance study. Participants then moved to less frequent regimens for 12 weeks. Every-other-week cohorts preserved up to 97% of the weight loss achieved during induction, while monthly regimens preserved up to 90%, compared with 61% among participants switched to placebo. An exploratory cohort kept on weekly 17.5mg dosing reached about 22% weight loss from baseline at week 33, with no plateau reported.
Roche's Phase II CT-388-104 study answers another question. Among 447 adults with type 2 diabetes and overweight or obesity, the 24mg enicepatide arm produced a 2.65 percentage-point reduction in HbA1c from an 8.1% baseline and 15.5% mean weight loss after 48 weeks. Roche said 90% reached HbA1c of 6.5% or below and 62% fell below 5.7%.
These results should not be collapsed into a cross-trial leaderboard. Different populations, designs and durations make that comparison unreliable.
Maintenance can change the cost of a treated year
Viking is attacking a burden that becomes more important after the first 20% of weight is lost: how many injections, how many delivery devices and how much patient effort are required to keep it off.
A weekly injection means roughly 52 dosing events a year. Every-other-week maintenance roughly halves that burden; monthly dosing reduces it to about one-quarter. If the weight-maintenance effect holds in larger and longer studies, that can lower the number of pens or syringes consumed per maintained patient-year and reduce adherence friction.
That is commercially different from winning the induction phase by another point of weight loss. Device filling and packaging capacity, administration burden and patient persistence all become part of the value proposition once obesity treatment is measured over years rather than months. Total drug-substance consumption depends on the maintenance dose and formulation, which this early study does not settle.
The evidence is still early. Viking's maintenance study is much smaller and shorter than a registrational Phase III obesity program, and the company has not established that the same retention of weight loss will persist over multiple years. Its broader subcutaneous obesity program is already in Phase III; the maintenance thesis still needs later-stage validation.
Roche's advantage is being tested on another axis. In a diabetes population, glycemic control has independent clinical value. The combination of a 2.65-point HbA1c decline and 15.5% weight loss gives enicepatide a metabolic profile that cannot be reduced to the obesity-only headline number.
For Lilly, Novo Nordisk and the next wave of challengers, the competitive field is becoming multidimensional: induction efficacy, maintenance interval, glycemic control, tolerability, device and administration intensity, and eventually cardiovascular outcomes and payer economics. Viking's data make injection burden an explicit competitive variable; Roche's make disease control harder to ignore.